Drug Landscape ›
formoterol - beclometasone ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Dyspnoea — 2 reports (18.18%) Chronic Obstructive Pulmonary Disease — 1 report (9.09%) Condition Aggravated — 1 report (9.09%) Coronavirus Test Positive — 1 report (9.09%) Fall — 1 report (9.09%) Hepatitis Toxic — 1 report (9.09%) Hyperglycaemia — 1 report (9.09%) Insomnia — 1 report (9.09%) Lung Neoplasm Malignant — 1 report (9.09%) Pain In Extremity — 1 report (9.09%)
Source database →
formoterol - beclometasone in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is formoterol - beclometasone approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for formoterol - beclometasone in United States?
Università degli Studi di Brescia is the originator. The local marketing authorisation holder may differ — check the official source linked above.